Acadia Pharmaceuticals (ACAD) PT Lowered to $28 at Morgan Stanley
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $21.43 +2.58%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $28.00 (from $50.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- BorgWarner (BWA) PT Raised to $95 at Wolfe Research, 'Bullish Takeaways from CEO Meetings'
- Resonac Holdings Corp (4004:JP) (SHWDY) PT Raised to JPY23,000 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
